Resistance to aspirin in increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels

Thrombosis Journal

Volumn 3, Issue , 2005, Pages

  Borna, Catharina ^a   Lazarowski, Eduardo ^b   van Heusden, Catharina ^b   Öhlin, Hans ^a   Erlinge, David ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; ADP; Aspirin; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN;

AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ST SEGMENT ELEVATION; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT FAILURE;

EID: 27444431936     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-3-10     Document Type: Article

References (28)

1. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
2. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-39.
3. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001, 345:494-502.
4. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-20.
5. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A: Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002, 107:45-49.
6. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cordiol 2001, 88:230-235.
7. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397-403.
8. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol E: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cordial 2003, 41:961-965.
9. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-5.
10. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA: Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Hemost 1995, 21 (Suppl 2):106-12.
11. Lazarowski ER, Boucher RC, Harden TK: Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extra-cellular nucleotide concentrations. J Biol Chem 2000, 275:31061-31068.
12. Levitt B, Head RJ, Westfall DP: High-pressure liquid chromatographic fluorometric detection of adenosine and adenine nucleotides: application to endogenous content and electrically induced release of adenyl purines in guinea pig vas deferens. Anal Biochem 1984, 137:93-100.
13. Kristensen SD, Bath PM, Martin JF: Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990, 24:19-23.
14. Milner PC, Martin JF: Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. Br Med J (Clin Res Ed) 1985, 290:1767-70.
15. Weber AA, Przytulski B, Schanz & Hohlfeld T, Schror K: Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 1:37-40.
16. Altman R, Luciardi HL, Muntaner J. Herrera RN: The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2004, 2:1.
17. Hillarp A, Lethagen S, Mattiasson I: Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-I activity. J Thromb Haemost 2003, 1:196-197.
18. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000, 311:591-5.
19. Rasmanis G, Vesterqvist O, Green K, Edhag O, Henriksson P: Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet 1988, 2(8605):245-7.
20. Heper G, Bayraktaroglu M: The importance of von Willebrand factor level and heart rate changes in acute coronary syndromes: a comparison with chronic ischemic conditions. Angiology 2003, 54:287-99.
21. Buerke M, Pittroff W, Meyer J, Darius H: Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995, 130(3 Pt 1):465-72.
22. Malhotra S, Sharma YP, Grover A, Majumdar S, Hanif SM, Bhargava VK, Bhatnagar A, Pandhi P: Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Intern Med J 2003, 33:350-4.
23. Gordon JL: Extracellular ATP: effects, sources and fate. Biochem J 1986, 233:309-19.
24. Vassort G: Adenosine 5′-Triphosphate: a P2-purinergic agonist in the myocardium. Physiological Reviews 2001:767-806.
25. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ:. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998, 97:350-355.
26. Storey RF, Newby LJ, Heptinstall S: Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001, 12:443-7.
27. Wang L, Östberg O, Wihlborg A-K, Brogren H, Jern S, Erlinge D: Quantification of ADP and ATP Receptor Expression in Human Platelets. J Thromb & Haem 2003, 1:330-336.
28. González-Alonso J, Olsen DB, Saltin B: Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery. Role of circulating ATP. Circ Res 2002, 91:1046-1055.